Ascendis Pharma A/S (ASND) Stock Price Today
Aura AI Summary
Key Stats
- $16.31BMarket Cap
- -Volume
- HealthSector
- $277.1852W High
- $189.7452W Low
- -Typical Hold Time
- $15.89BEnterprise Value
- -Div Yield
- -Trading Activity
Track Ascendis Pharma A/S (ASND) stock price today on Pluang, updated in real time with live charts and market data. Over the past 52 weeks, Ascendis Pharma A/S has traded between a low of $189.74 and a high of $277.18, highlighting its annual price range. Buy and sell Ascendis Pharma A/S shares on Pluang with fractional shares and real-time market data — safe and OJK-regulated.
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Most Recent News
Director Carande buys 2,101 shares of United Community Banks, signaling confidence.
Director Carande has purchased 2,101 shares of United Community Banks. This insider buying may indicate confidence in the company's future prospects. Investors often view such transactions as a positive signal, potentially influencing market sentimen...
Chip stocks fall despite bond yield relief; NVIDIA holds steady ahead of earnings report.
Chip stocks like Intel, AMD, and Broadcom fell 4-5% despite a drop in long-term Treasury yields, which usually supports growth stocks. This selloff is seen as portfolio-level trimming of AI hardware exposure ahead of NVIDIA's earnings report on Augus...
Microsoft's AI-driven growth hits $100B Azure revenue, but stock lags despite strong earnings and AI expansion.
Microsoft's Azure cloud service surpassed $100 billion in annual revenue, and its AI tool Copilot reached over 30 million paid seats, driving a 17.8% revenue increase and 31.3% net income growth in FY2026. Despite these gains, Microsoft shares remain...
People also bought
Frequently Asked Questions
All investments involve risks and the possibility of a loss in investment value. Past performance is not indicative of future results. Historical performance, expected returns, and probability projections are provided for informational and illustrative purposes only.